Biomea Fusion, Inc. Share Price & Technical Analysis
BMEA · $1.42 (+3.65%)
Healthcare / Biotechnology
$1.42
+3.65%
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, -7% avg return in past 3 year May month.
12% return in 2026, -10% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | 27% | 7% | -7% | 0% | – | – | – | – | – | – | – | 12% |
| 25 | 5% | -27% | -28% | -5% | -33% | 20% | -6% | 25% | 0% | -30% | -21% | 9% | -91% |
| 24 | 25% | -4% | -15% | -31% | -2% | -59% | 24% | 24% | 38% | -5% | -24% | -46% | -74% |
| 23 | 13% | 35% | 137% | -5% | 15% | -35% | 4% | -24% | -18% | -27% | 47% | -6% | 134% |
| 22 | -3% | -11% | -26% | -32% | 83% | 118% | -11% | 10% | -12% | 12% | -36% | 15% | 107% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$110.98M
P/E ratio
—
52W high
$3.08
52W low
$0.87
Volume
9,11,026
Beta
-0.34
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Biomea Fusion, Inc. share price today?
- Biomea Fusion, Inc. (BMEA) last traded around $1.42 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BMEA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BMEA. Download the app for real-time alerts.
- How can I analyze Biomea Fusion, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.